Insider · CIK 0002028309
Barbara Leyman
officer
Files at STRO (SUTRO BIOPHARMA, INC.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 8, 2025 | STRO SUTRO BIOPHARMA, INC. | MOption exercise Common Stock | +25,000 | $0.00 | $0 | 25,000 | Aug 26, 2025 |
| Jul 8, 2025 | STRO SUTRO BIOPHARMA, INC. | FTax withholding Common Stock | -8,944 | $0.78 | $6,976 | 16,056 | Aug 26, 2025 |
| Jul 8, 2025 | STRO SUTRO BIOPHARMA, INC. | MOption exercise Restricted Stock Units (RSUs)derivative | -25,000 | $0.00 | $0 | 75,000 | Aug 26, 2025 |
| Apr 4, 2025 | STRO SUTRO BIOPHARMA, INC. | AGrant or award Stock Option (Right to Buy)derivative | +91,000 | $0.00 | $0 | 91,000 | Apr 8, 2025 |
| Apr 4, 2025 | STRO SUTRO BIOPHARMA, INC. | AGrant or award Restricted Stock Units (RSUs)derivative | +84,500 | $0.00 | $0 | 84,500 | Apr 8, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.